Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) Programs at the SITC 37th Annual Meeting

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,David Borah ,Lukas Stanczuk ,Kristin Hurov ,Johanna Lahdenranta ,Anna Licht ,Sarah Sutton ,Alexandra Rezvaya ,Society For Immunotherapy Of Cancer ,Nasdaq ,Bicycle Therapeutics ,Annual Meeting ,Lia Luus ,Bicycle Toxin Conjugate ,Cancer Research United Kingdom Centre ,Capital Markets Investor Relations ,Bicycle ,Herapeutics ,Present ,Five ,Posters ,Ighlighting ,Reclinical ,Data ,Rom ,Humor ,Argeted ,Immune ,Fell ,Agonist ,Ica ,Programs ,Itc ,7th ,Nnual ,Meeting ,